270 related articles for article (PubMed ID: 31907570)
1. Decreases in the Psoas Muscle Index Correlate More Strongly with Survival than Other Prognostic Markers in Esophageal Cancer After Neoadjuvant Chemoradiotherapy Plus Esophagectomy.
Kawakita Y; Motoyama S; Sato Y; Wakita A; Nagaki Y; Imai K; Minamiya Y
World J Surg; 2020 May; 44(5):1559-1568. PubMed ID: 31907570
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy.
Ozawa Y; Nakano T; Taniyama Y; Sakurai T; Onodera Y; Kamiya K; Hikage M; Sato C; Takaya K; Konno T; Unno M; Kamei T
Esophagus; 2019 Oct; 16(4):345-351. PubMed ID: 30980203
[TBL] [Abstract][Full Text] [Related]
3. Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy.
Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
BMC Cancer; 2021 Nov; 21(1):1192. PubMed ID: 34753448
[TBL] [Abstract][Full Text] [Related]
4. SUV
Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
World J Surg Oncol; 2021 Apr; 19(1):105. PubMed ID: 33836789
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of preoperative psoas muscle index as a measure of nutritional status in patients with esophageal cancer receiving neoadjuvant therapy.
Nakayama T; Furuya S; Kawaguchi Y; Shoda K; Akaike H; Hosomura N; Amemiya H; Kawaida H; Sudoh M; Kono H; Ichikawa D
Nutrition; 2021 Oct; 90():111232. PubMed ID: 33964490
[TBL] [Abstract][Full Text] [Related]
6. PET-Uptake Reduction into Lymph Nodes After Neoadjuvant Therapy is Highly Predictive of Prognosis for Patients Who have Thoracic Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy Plus Esophagectomy.
Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Kemuriyama K; Sasaki Y; Imai K; Maeda E; Minamiya Y
Ann Surg Oncol; 2022 Feb; 29(2):1336-1346. PubMed ID: 34355333
[TBL] [Abstract][Full Text] [Related]
7. Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Saeki H; Nakashima Y; Zaitsu Y; Tsuda Y; Kasagi Y; Ando K; Imamura Y; Ohgaki K; Ito S; Kimura Y; Egashira A; Oki E; Morita M; Maehara Y
Surg Today; 2016 Mar; 46(3):261-7. PubMed ID: 25740123
[TBL] [Abstract][Full Text] [Related]
8. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy.
Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486
[TBL] [Abstract][Full Text] [Related]
9. Sarcopenia assessed by skeletal muscle mass volume is a prognostic factor for oncological outcomes of rectal cancer patients undergoing neoadjuvant chemoradiotherapy followed by surgery.
Horie K; Matsuda T; Yamashita K; Hasegawa H; Utsumi M; Urakawa N; Kanaji S; Oshikiri T; Kakeji Y
Eur J Surg Oncol; 2022 Apr; 48(4):850-856. PubMed ID: 34756762
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma.
Suzuki T; Okamura A; Watanabe M; Mine S; Imamura Y; Asari T; Osumi H; Nakayama I; Ichimura T; Ogura M; Ooki A; Takahari D; Yamaguchi K; Chin K
Ann Surg Oncol; 2020 May; 27(5):1510-1517. PubMed ID: 31820213
[TBL] [Abstract][Full Text] [Related]
11. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Neoadjuvant Chemoradiotherapy Following Esophagectomy with Japanese-style Extended 3-Field Lymphadenectomy for Thoracic Esophageal Cancer.
Motoyama S; Sato Y; Sasaki T; Wakita A; Kawakita Y; Liu J; Nagaki Y; Saito H; Imai K; Konno H; Mizusawa KT; Minamiya Y
Anticancer Res; 2017 Oct; 37(10):5837-5843. PubMed ID: 28982909
[TBL] [Abstract][Full Text] [Related]
13. Quantity and Quality of Skeletal Muscle as an Important Predictor of Clinical Outcomes in Patients with Esophageal Cancer Undergoing Esophagectomy after Neoadjuvant Chemotherapy.
Ishida T; Makino T; Yamasaki M; Yamashita K; Tanaka K; Saito T; Yamamoto K; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Eguchi H; Doki Y
Ann Surg Oncol; 2021 Nov; 28(12):7185-7195. PubMed ID: 33876359
[TBL] [Abstract][Full Text] [Related]
14. Long-term variation in psoas muscle mass index is affected by short-term loss after esophagectomy in survivors of esophageal cancer.
Nishimura E; Kawakubo H; Matsuda S; Fukuda K; Nakamura R; Kitagawa Y
Dis Esophagus; 2023 Feb; 36(3):. PubMed ID: 36073920
[TBL] [Abstract][Full Text] [Related]
15. Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation.
Xiao X; Fang PH; Zhou JF; Li XK; Shang QX; Yang YS; Luan SY; Chen LQ; Yuan Y
Ann Surg Oncol; 2024 Jun; 31(6):3819-3829. PubMed ID: 38245646
[TBL] [Abstract][Full Text] [Related]
16. Impact of change in the Naples prognostic score after neoadjuvant chemoradiotherapy on survival in esophageal squamous cell carcinoma patients.
Zhang H; Xiao X; Luan S; Li X; Sun S; Yuan Y
Saudi Med J; 2024 May; 45(5):481-489. PubMed ID: 38734428
[TBL] [Abstract][Full Text] [Related]
17. Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy.
Takaichi S; Tomimaru Y; Kobayashi S; Toya K; Sasaki K; Iwagami Y; Yamada D; Noda T; Takahashi H; Asaoka T; Tanemura M; Doki Y; Eguchi H
Ann Surg Oncol; 2023 Apr; 30(4):2458-2468. PubMed ID: 36575288
[TBL] [Abstract][Full Text] [Related]
18. Verification of the Optimal Interval Before Esophagectomy After Preoperative Neoadjuvant Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer.
Wakita A; Motoyama S; Sato Y; Nagaki Y; Fujita H; Terata K; Imai K; Minamiya Y
Ann Surg Oncol; 2021 Apr; 28(4):2101-2110. PubMed ID: 33051740
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Radiation-Associated Esophageal Squamous Cell Carcinoma: The MSKCC Experience.
Nobel TB; Barbetta A; Hsu M; Tan KS; Pinchinat T; Schlottmann F; Bains MS; Ku GY; Wu AJ; Patti MG; Jones DR; Molena D
J Gastrointest Surg; 2019 Jan; 23(1):11-22. PubMed ID: 30215197
[TBL] [Abstract][Full Text] [Related]
20. Utility of preoperative chemoradiotherapy for advanced esophageal carcinoma.
Kuroda J; Yoshida M; Kitajima M; Yanagisawa A; Matsubara T; Yamaguchi T; Osamura Y; Ohta K; Kubota K; Beck Y; Yamashita Y
J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():88-94. PubMed ID: 22486878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]